QIBA Collaborations: Difference between revisions

From QIBA Wiki
Jump to navigation Jump to search
← Older edit
VisualWikitext
mNo edit summary
 
(37 intermediate revisions by 3 users not shown)
Line 1: Line 1:
==Collaborative Efforts==
==Collaborative Efforts==


[http://www.radiology.jp/j-qiba/english/index.htmlJapan Quantitative Imaging Biomarker Alliance (J-QIBA)]
QIBA is grateful for the support of our collaborators.


*Our society partners help QIBA with the development and implementation of quantitative imaging biomarkers, which are essential to precision medicine and AI tools.
*The companies offer conformance testing services to help Profile users achieve high-quality quantitative imaging results.


::[[Image:Prevent Cancer Foundation.png|120px]]https://preventcancer.org/
We work together to provide efficient and validated methods for quantifying biomedical imaging results necessary for optimal patient care, clinical research, and new therapy development.


*[[Media:March-April2018_PCF_Newsletter_LungCancerTimeline.pdf|March / April 2018 Prevent Cancer Foundation Newsletter]]






::[[Image:Cancer Moonshot.jpg|120px]]
:[[Image:Logos-Update-Wiki-31JULY2023.png|800px]]


'''Cancer Moonshot & QIBA''' [https://medium.com/cancer-moonshot]
==Collaboration Highlights==
*RSNA/QIBA is very pleased to announce that two of the QIBA Profiles relevant to cancer patients have been referenced and supported by the Federal Cancer Moonshot Initiative (https://medium.com/cancer-moonshot) as ways to advance research and outcomes.  
*EARL II Pilot Study - Ongoing study to assess international imaging site conformance to the QIBA FDG-PET/CT Profile -August 2022
*The FDG-PET/CT and CT Volumetry Profiles have been submitted as the most advanced Profiles to-date. Our sincerest appreciation to all of the QIBA participants who helped us arrive at this important milestone.
*RadSite Pilot Study - Ongoing study to assess accredited imaging site conformance to the QIBA FDG-PET/CT Profile - August 2022
 
*The QIBA PET Amyloid Profile has advanced to Stage 3 (Clinically Feasible), and can be found on the QIBA Profiles page: https://qibawiki.rsna.org/index.php/Profiles
 
{| style="width:80%" border="1" cellpadding="2"
!<font color="green">'''Organization'''</font>
!<font color="green">'''link'''</font>
 
|-
|'''AIUM - American Institute of Ultrasound in Medicine'''
|https://www.aium.org/
|-
|'''CaliberMRI'''
|https://qmri.com/
|-
|'''EARL, ''Research4Life'', under the umbrella of the European Association of Nuclear Medicine (EANM)'''
|https://www.eanm.org/earl-research4life/
|-
|'''EIBALL - European Imaging Biomarkers Alliance, European Society of Radiology (ESR)'''
|https://www.myesr.org/about/organisation/statutory-committees/research-committee
|-
|'''EIBIR - European Institute for Biomedical Imaging'''
|https://www.eibir.org/
|-
|'''Invicro'''
|https://invicro.com/
|-
|'''ISMRM - International Society for Magnetic Resonance in Medicine'''
|https://www.ismrm.org/
|-
|'''Japan Quantitative Imaging Biomarker Alliance (J-QIBA), a part of the Japan Radiological Society'''
|http://www.radiology.jp/j-qiba/english/index.html
|-
|'''Prevent Cancer Foundation'''
|https://www.preventcancer.org/
|-
|'''RadSite'''
|https://radsitequality.com/
|-
|'''SNMMI - Society of Nuclear Medicine and Molecular Imaging'''
|http://www.snmmi.org/
|}


==Funding Agency==
==Funding Agency==
[[Image:NIBIB Acknowledgement.jpg|400px]]
[[Image:NIBIB Acknowledgement.jpg|400px]]

Latest revision as of 15:38, 31 July 2023

Collaborative Efforts

QIBA is grateful for the support of our collaborators.

  • Our society partners help QIBA with the development and implementation of quantitative imaging biomarkers, which are essential to precision medicine and AI tools.
  • The companies offer conformance testing services to help Profile users achieve high-quality quantitative imaging results.

We work together to provide efficient and validated methods for quantifying biomedical imaging results necessary for optimal patient care, clinical research, and new therapy development.



Collaboration Highlights

  • EARL II Pilot Study - Ongoing study to assess international imaging site conformance to the QIBA FDG-PET/CT Profile -August 2022
  • RadSite Pilot Study - Ongoing study to assess accredited imaging site conformance to the QIBA FDG-PET/CT Profile - August 2022


Organization link
AIUM - American Institute of Ultrasound in Medicine https://www.aium.org/
CaliberMRI https://qmri.com/
EARL, Research4Life, under the umbrella of the European Association of Nuclear Medicine (EANM) https://www.eanm.org/earl-research4life/
EIBALL - European Imaging Biomarkers Alliance, European Society of Radiology (ESR) https://www.myesr.org/about/organisation/statutory-committees/research-committee
EIBIR - European Institute for Biomedical Imaging https://www.eibir.org/
Invicro https://invicro.com/
ISMRM - International Society for Magnetic Resonance in Medicine https://www.ismrm.org/
Japan Quantitative Imaging Biomarker Alliance (J-QIBA), a part of the Japan Radiological Society http://www.radiology.jp/j-qiba/english/index.html
Prevent Cancer Foundation https://www.preventcancer.org/
RadSite https://radsitequality.com/
SNMMI - Society of Nuclear Medicine and Molecular Imaging http://www.snmmi.org/

Funding Agency

Retrieved from "https://qibawiki.rsna.org/index.php?title=QIBA_Collaborations&oldid=19114"